Economic and humanistic burden of external genital warts

PharmacoEconomics

Volumn 30, Issue 1, 2012, Pages 1-16

  Raymakers, Adam J N ^a   Sadatsafavi, Mohsen ^a   Marra, Fawziah ^a,b   Marra, Carlo A ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c PROVIDENCE HEALTH CARE RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CONDYLOMA ACUMINATUM; CONSULTATION; COST BENEFIT ANALYSIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; QUALITY OF LIFE; SYSTEMATIC REVIEW; TREATMENT DURATION;

CONDYLOMATA ACUMINATA; COST OF ILLNESS; HEALTH CARE COSTS; HUMANS; QUALITY OF LIFE;

EID: 83455257868     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11591170-000000000-00000     Document Type: Article

References (69)

1. Burchell AN, Winer RL, de Sanjosé S, et al. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006 Aug 21; 24 Suppl. 3: S52-61 (Pubitemid 44293018)
2. Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 2007 Nov; 107 (2 Suppl. 1): S2-5 (Pubitemid 47559075)
3. Kaufman RH, Adam E, Vonka V. Human papillomavirus infection and cervical carcinoma. Clin Obstet Gynecol 2000 Jun; 43 (2): 363-80 (Pubitemid 30450552)
4. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997 May 5; 102 (5A): 3-8 (Pubitemid 127695953)
5. Fenton KA, Lowndes CM. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sex Transm Infect 2004 Aug; 80 (4): 255-63 (Pubitemid 39070785)
6. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection.Vaccine 2006Mar 30; 24 Suppl. 1: S1-15
7. Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J 2006; 12 (3): 5
8. Beutner KR, Wiley DJ, Douglas JM, et al. Genital warts and their treatment. Clin InfectDis 1999 Jan; 28 Suppl. 1: S37-56 (Pubitemid 29249960)
9. Dediol I, Buljan M, Vurnek-A Ivkoviä M, et al. Psychological burden of anogenital warts. J Eur Acad Dermatol Venereol 2009 Sep; 23 (9): 1035-8
10. Clarke P, Ebel C, Catotti DN, et al. The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS 1996 Jun; 7 (3): 197-200 (Pubitemid 26191688)
11. Lawrence S,WalzmanM, Sheppard S, et al. The psychological impact caused by genital warts: has theDepartment ofHealth's choice of vaccination missed the opportunity to prevent such morbidity? Int J STD AIDS 2009 Oct; 20 (10): 696-700
12. Glanville, Fleetwood K, Yellowlees A, et al. Development and testing of search filters to identify economic evaluations in MEDLINE and EMBASE. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2009 [online]. Available from URL: http://www.cadth.ca/in dex.php/en/hta/reports-publications/ search/publication/934 [Accessed 2010 Oct 29]
13. Organization for Economic Co-operation and Development (OECD). PPPs and exchange rates [online]. Available from URL: http://stats.oecd.org/Index.aspx? datasetcode=SNA-TABLE4 [Accessed 2010 Jul 23]
14. USBureau of Labor Statistics. Archived consumer price index detailed report information [online]. Available from URL: http://www.bls.gov/cpi/cpi-dr. htm [Accessed 2011 Jul 26]
15. Richwald G, Langley P. Cost of care and treatment patterns for external genital warts (EGWs) in OB/GYN practices in the United States [abstract]. Int J STDAIDS 2001; 12 Suppl. 2: 126
16. Sénécal M, Brisson M, Maunsell E, et al. Loss of quality of life associated with genital warts: baseline analyses from a prospective study. Sex Transm Infect 2011 Apr; 87 (3): 209-15
17. Herse F, Reissell E. The annual costs associated with human papillomavirus types 6, 11, 16, and 18 infections in Finland. Scand J Infect Dis 2011 Mar; 43 (3): 209-15
18. Hoy T, Singhal PK, Willey VJ, et al. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009 Oct; 25 (10): 2343-51
19. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003 Jun 1; 36 (11): 1397-403 (Pubitemid 36702873)
20. Hillemanns P, Breugelmans JG, Gieseking F, et al. Estimation of the incidence of genital warts and the cost of illness inGermany: a cross-sectional study. BMC Infect Dis 2008 Jun 2; 8: 76
21. Castellsagué X, Cohet C, Puig-Tintoré LM, et al. Epidemiology and cost of treatment of genital warts in Spain. Eur J Public Health 2009 Jan; 19 (1): 106-10
22. Annemans L, Rémy V, Lamure E, et al. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. J Med Econ 2008; 11 (1): 135-50 (Pubitemid 351613819)
23. Merito M, Largeron N, Cohet C, et al. Treatment patterns and associated costs for genital warts in Italy. Curr Med Res Opin 2008 Nov; 24 (11): 3175-83
24. Pirotta M, Stein AN, Conway EL, et al. Genital warts incidence and health care resource utilisation in Australia. Sex Transm Infect 2010 Jun; 86 (3): 181-6
25. Brown RE, Breugelmans JG, Theodoratou D, et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006 Apr; 22 (4): 663-70
26. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 2009 Apr; 85 (2): 111-5
27. van der Meijden WI, Notowicz A, Blog FB, et al. A retrospective analysis of costs and patterns of treatment for external genital warts in the Netherlands. Clin Ther 2002 Jan; 24 (1): 183-96 (Pubitemid 34117533)
28. Dee A, Howell F, O'Connor C, et al. Determining the cost of genital warts: a study from Ireland. Sex Transm Infect 2009 Sep; 85 (5): 402-3
29. Langley PC, White DJ, Drake SM. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 2004 Aug; 15 (8): 501-8 (Pubitemid 39120231)
30. Woodhall SC, Jit M, Cai C, et al. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis 2009 Aug; 36 (8): 515-21
31. Brisson M, Van de Velde N, De Wals P, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007 Jul 20; 25 (29): 5399-408 (Pubitemid 46977529)
32. Marra C, Ogilvie G, Gastonguay L, et al. Patients with genital warts have a decreased quality of life. Sex Transm Dis 2009 Apr; 36 (4): 258-60
33. Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008 Jun; 84 (3): 161-6 (Pubitemid 351871484)
34. Badia X, Colombo JA, Lara N, et al. Combination of qualitative and quantitative methods for developing a new health related quality of life measure for patients with anogenital warts. Health Qual Life Outcomes 2005 Apr 7; 3: 24
35. Vilata JJ, Varela JA, Olmos L, et al. Validation and clinical use of the CECA, a disease-specific quality of life questionnaire for patients with anogenital condylomata acuminata. Acta Derm Venereol 2008; 88 (3): 257-62 (Pubitemid 351743869)
36. Wang K, Jeng C, Yang Y, et al. The psychological impact of illness among women experiencing human papillomavirusrelated illness or screening interventions. J Psychosom Obstet Gynaecol 2010 Mar; 31 (1): 16-23
37. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005; 23 (11): 1107-22 (Pubitemid 41633402)
38. Lacey CJN, Goodall RL, Tennvall GR, et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003 Aug; 79 (4): 270-5 (Pubitemid 37026341)
39. Ginsberg GM, Fisher M, Ben-Shahar I, et al. Cost-utility analysis of vaccination against HPV in Israel. Vaccine 2007 Sep 17; 25 (37-38): 6677-91 (Pubitemid 47337133)
40. Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010 Apr; 26 (2): 183-91
41. Insinga RP, Dasbach EJ, Elbasha EH, et al. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007 Dec 21; 26 (1): 128-39 (Pubitemid 350218187)
42. Langley PC, Tyring SK, Smith MH. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Manag Care 1999 Jan; 5 (1): 69-77 (Pubitemid 29061607)
43. Langley PC, Richwald GA, Smith MH. Modeling the impact of treatment options in genital warts: patient-applied versus physician-administered therapies. Clin Ther 1999 Dec; 21 (12): 2143-55 (Pubitemid 30043928)
44. Birley H, Clark F, Sparks R. Cost-effectiveness of imiquimod for anogenital warts. Int J STD AIDS 2002 Sep; 13 (9): 647; author reply 647-8
45. Williams P, von Krogh G. The cost-effectiveness of patientapplied treatments for anogenital warts. Int J STD AIDS 2003 Apr; 14 (4): 228-34 (Pubitemid 36403371)
46. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006; 28: 88-100 (Pubitemid 44289092)
47. Newall AT, Beutels P, Wood JG, et al. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007 Apr; 7 (4): 289-96 (Pubitemid 46414076)
48. Van de Velde N, Brisson M, Boily M. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007 Apr 1; 165 (7): 762-75 (Pubitemid 46434599)
49. Bergeron C, Largeron N, McAllister R, et al. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 2008; 24 (1): 10-9 (Pubitemid 351158538)
50. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337: a769
51. Kulasingam SL, Benard S, Barnabas RV, et al. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 2008 Feb 15; 6: 4
52. Chesson HW, Ekwueme DU, Saraiya M, et al. Costeffectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008 Feb; 14 (2): 244-51 (Pubitemid 351213674)
53. Szucs TD, Largeron N, Dedes KJ, et al. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008 May; 24 (5): 1473-83 (Pubitemid 351741581)
54. Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008 Jul; 115 (8): 947-56 (Pubitemid 351841762)
55. Goldie SJ, O'Shea M, Campos NG, et al. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVIeligible countries. Vaccine 2008 Jul 29; 26 (32): 4080-93
56. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008 Aug 21; 359 (8): 821-32
57. Dasbach EJ, Insinga RP, Yang YC, et al. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pac J Cancer Prev 2008 Sep; 9 (3): 459-66
58. Brisson M, Van de Velde N, Boily M. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009; 12 (5-6): 343-51
59. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339: b3884
60. Rogoza RM, Westra TA, Ferko N, et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 2009 Jul 30; 27 (35): 4776-83
61. Chuck A. Cost-effectiveness of 21 alternative cervical cancer screening strategies. Value Health 2010 Mar-Apr; 13 (2): 169-79
62. Dasbach EJ, Nagy L, Brandtmü ller A, et al. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) inHungary. J Med Econ 2010Mar; 13 (1): 110-8
63. Langley PC. A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts. J Med Econ 2010 Mar; 13 (1): 1-7
64. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996 Nov; 10 (5): 460-6 (Pubitemid 26359874)
65. Langley PC, White DJ, Drake SM. Patterns of treatment and resource utilization in the treatment of external genital warts in England and Wales. Int J STD AIDS 2004 Jul; 15 (7): 473-8 (Pubitemid 38961845)
66. Lacey CJN, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006 Aug 31; 24 Suppl. 3: S3/35-41
67. Chesson HW, Blandford JM, Gift TL, et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004 Feb; 36 (1): 11-9
68. Pauly MV, Nicholson S, Polsky D, et al. Valuing reductions in on-the-job illness: 'presenteeism' from managerial and economic perspectives. Health Econ 2008 Apr; 17 (4): 469-85 (Pubitemid 351517406)
69. Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. Soc Sci Med 2011 Jan; 72 (2): 185-92